Urelumab (BMS-663513 or anti-4-1BB antibody) is a fully human, non‐ligand binding, CD137 agonist immunoglobulin‐γ 4 (IgG4) monoclonal antibody.[1] It was developed utilizing Medarex's UltiMAb(R) technology by Bristol-Myers Squibb for the treatment of cancer and solid tumors.[2] Urelumab promotes anti-tumor immunity, or an immune response against tumor cells, via CD137 activation.[2][3] The application of Urelumab has been limited due to the fact that it can cause severe liver toxicity.[4][5][6]
^Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, et al. (May 2020). "Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma". American Journal of Hematology. 95 (5): 510–520. doi:10.1002/ajh.25757. PMC 7383599. PMID 32052473.
^ ab"Urelumab Overview".
^"Urelumab". National Cancer Institute.
^Ho SK, Xu Z, Thakur A, Fox M, Tan SS, DiGiammarino E, et al. (April 2020). "Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity". Molecular Cancer Therapeutics. 19 (4): 1040–1051. doi:10.1158/1535-7163.MCT-19-0608. PMID 31974274. S2CID 210882192.
^Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, Yang X (May 2019). "Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity". Nature Communications. 10 (1): 2141. Bibcode:2019NatCo..10.2141Q. doi:10.1038/s41467-019-10088-1. PMC 6526162. PMID 31105267. S2CID 256641802.
^Etxeberria I, Bolaños E, Teijeira A, Garasa S, Yanguas A, Azpilikueta A, et al. (June 2021). "Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic". Proceedings of the National Academy of Sciences of the United States of America. 118 (26). Bibcode:2021PNAS..11825930E. doi:10.1073/pnas.2025930118. PMC 8255787. PMID 34172583.
Urelumab (BMS-663513 or anti-4-1BB antibody) is a fully human, non‐ligand binding, CD137 agonist immunoglobulin‐γ 4 (IgG4) monoclonal antibody. It was...
and Induced by Lymphocyte Activation (ILA). Targeted by Bristol Myers' Urelumab, a CD137 agonist antibody, in early trials with anti-PDL1 (CD274) mAbs;...
Currently, Utomilumab is the only mAb targeting CD137 on the market. Urelumab trials were temporarily halted due to risk of liver toxicity. Utomilumab...
Global Information
(what is this?) (verify)